Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.
Center for Cancer Research, National Cancer Institute, NIH Maryland, Bethesda, USA.
World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20.
The SIU (Société Internationale d'Urologie)-ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.
国际泌尿外科学会（SIU）-国际泌尿疾病咨询委员会（ICUD）转移性膀胱癌系统治疗工作组总结了上述主题的最新研究结果，并根据已发表的证据得出结论和建议。在欧洲和美国，转移性 UC 的治疗最近发生了很大变化，主要涉及从化疗转向免疫检查点抑制剂。在铂类耐药疾病中尤其如此，其中存在支持性随机数据。FDA 已批准五种检查点抑制剂在这种情况下使用：avelumab、atezolizumab、durvalumab、nivolumab 和 pembrolizumab。nivolumab、pembrolizumab 和 atezolizumab 已在欧洲获得批准。
